[1] R. Saldova, et al., Levels of specific serum N-glycans identify breast cancer patients with higher circulating tumor cell counts, Ann. Oncol. 22 (2011) 1113–1119.

[2] U.M. Abd Hamid, et al., A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression, Glycobiology 18 (2008) 1105

[3] Z. Kyselova, et al., Breast cancer diagnosis and prognosis through quantitative measurements of serum glycan profiles, Clin. Chem. 54 (2008) 1166–1175.

[4] A. Pierce, et al., Levels of specific glycans significantly distinguish lymph node

[5] de Leoz, M. L., et al., (2011) High-mannose glycans are elevated during breast cancer progression. Mol. Cell. Proteomics 10, M110.00271

[6] Alley, W. R., Jr., et al., (2010) Chip-based reversed-phase liquid chromatography-mass spectrometry of permethylated N-linked glycans: a potential methodology for cancerbiomarker discovery. Anal. Chem. 82, 5095–5106

[7] J. Bones, et al., Ultra performance liquid chromatographic profiling of serum N-glycans for fast and efficient identification of cancer associated alterations in glycosylation, Anal. Chem. 82 (2010) 10208–10215.

[8] J. Bones, et al., Glycomic and glycoproteomic analysis of serum from patients with stomach cancer reveals potential markers arising from host defence response mechanisms, J. Proteome Res. 10 (2011) 1246–1265.

[9] Goldman, R., et al., (2009) Detection of hepatocellular carcinoma using glycomic analysis. Clin. Cancer Res. 15, 1808–1813

[10] Liu, X. E., et al., (2007) N-glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus. Hepatology 46, 1426–1435

[11] K. Noda, et al, Gene expressionof α1-6 fucosyltransferase in human hepatoma tissues: a possible implicationfor increased fucosylation of α-fetoprotein, Hepatology 28 (1998), 944–952.

[12] Y. Sato, et al.,Early recognition of hepatocellular carcinoma based on altered profiles of alphafetoprotein,N. Engl. J. Med. 328 (1993) 1802–1806.

[13] J.N. Arnold, R. Saldova, M.C. Galligan, T.B. Murphy, Y. Mimura-Kimura, J.E. Telford, A.K. Godwin, P.M. Rudd, Novel glycan biomarkers for the detection of lung cancer, J. Proteome Res. 10 (2011) 1755–1764.

[14] Kim, Y. G., et al., (2009) Rapid and high-throughput analysis of N-glycans from ovarian cancer serum using a 96-well plate platform. Anal. Biochem. 391, 151–153.

[15]  R. Saldova, et al., Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG, Glycobiology 17 (2007) 1344.

[16] Alley, W. R., Jr., et al., (2012) N-linked glycan structures and their expressions change in the blood sera of ovarian cancer patients. J. Proteome Res. 11, 2282–2300

[17] Kronewitter, S. R., et al., (2012) The glycolyzer: automated glycan annotation software for high performance mass spectrometry and its application to ovarian cancer glycan biomarker discovery. Proteomics 12, 2523–2538

[18] Storr SJ, et al., The O-linked glycosylation of secretory/shed MUC1 from an advanced breast cancer patient’s serum. Glycobiology 2008, 18(6):456-462.

[19] R. Saldova, et al., Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia, Glycobiology 21 (2011) 195–205.

[20] A. Sarrats, et al., Glycan characterization of PSA 2-DE subforms from serum and seminal plasma, OMICS: A J. of Integr. Biol. 14 (2010) 465–474.

[21] A. Sarrats, et al., Differential percentage of serum prostate-specific antigen subforms suggests a new way to improve prostate cancer diagnosis, Prostate 70 (2010) 1–9.

[22] Hua, S., et al., (2011) Comprehensive native glycan profiling with isomer separation and quantitation for the discovery of cancer biomarkers. Analyst 136, 3663–3671.

[23] N. Okuyama, et al., Fucosylated haptoglobin is a novel marker for pancreatic cancer: a detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation, Int. J. Cancer 118 (2006) 2803–2808.

[24] E. Miyoshi, M. Nakano, Fucosylated haptoglobin is a novel marker for pancreatic cancer: detailed analyses of oligosaccharide structures, Proteomics 8 (2008) 3257–3262.

[25] Nakano M, et al., Site specific analysis of N-glycans on haptoglobin in sera of patients with pancreatic cancer: a novel approach for the development of tumor markers. Int J Cancer 2008;122: 2301–9.

[26] Kukowska-Latallo JF, et al., A cloned human cDNA determines expression of a mouse stagespecific embryonic antigen and the Lewis blood group a(1,3/1,4)fucosyltransferase. Genes Dev 1990;4:1288–303.

[27] Hanski C, et al.,  Fucosyltransferase III and sialyl-Le(x) expression correlate in cultured colon carcinoma cells but not in colon carcinoma tissue. Glycoconj J 1996;13:727–33.

[28] Majuri ML, et al., Expression and function of a2,3-sialyl- and a,3/l,4- fucosyltransferases in colon adenocarcinoma cell lines: role in synthesis of E-selectin counter-receptors. Int J Cancer 1995;63:551–9.

[29] Ercan et al. Hypogalactosylation of serum N-glycans fails to predict clinical response to methotrexate and TNF inhibition in rheumatoid arthritis.Arthritis Research & Therapy 2012, 14:R43

[30] James N. Arnold et al., Mannan binding lectin and its interaction with immunoglobulins inhealth and in disease, Immunology Letters 106 (2006) 103–110

[31] Pauline M. Rudd et al. Glycosylation and the Immune System. Science 291, 2370 (2001)

[32] Arnold, J. N:, et al., The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu. Rev. Immunol. 25, 21-50 (2007)

[33] Gaya Thanabalasingham, G. Lauc, et al., “Mutations in HNF1A Result in Marked Alterations of Plasma Glycan Profile“, Diabetes 2013, 62, 1329.

[34] Zihao Wang, et al., “Site-Specific GlcNAcylation of Human Erythrocyte Proteins“, Diabetes 2009, 59, 309 .